Authors: Viral N Shah, Terry Dex, Luigi Meneghini, Amélie Rodrigues, William H Polonsky
Abstract
Aims: In Soli-CGM, treatment with iGlarLixi (insulin glargine 100 U/mL and lixisenatide 33 μg/mL) in insulin-naive adults with suboptimally controlled type 2 diabetes (T2D; haemoglobin A1c 9%-13% on ≥2 oral antihyperglycaemic agents (OADs) ± glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy) increased time in range (TIR; primary endpoint) from 26.4% at baseline to 52.7% at Week 16. This exploratory analysis examined the impact of treatment with iGlarLixi on patient-reported treatment satisfaction.
Materials and methods: Soli-CGM was a single-arm, 16-week, multicentre, interventional, open-label, phase 4 study using blinded continuous glucose monitoring (CGM; FreeStyle Libre Pro) to assess glycaemic metrics (N = 124). CGM data were collected for a 2-week period before initiation of iGlarLixi, and after treatment with iGlarLixi (Weeks 14-16). Treatment satisfaction was assessed using the Diabetes Medication Treatment Satisfaction Tool (DM-SAT, which comprises four domains: well-being, medical control, lifestyle and convenience), at baseline and end-of-treatment. Association of TIR and overall satisfaction (sum of all items) was also assessed.
Results: Overall, 118 (95.9%) and 107 (87.0%) participants completed the DM-SAT at baseline and Week 16, respectively. Mean overall score increased by 0.18, from 0.59 (baseline) to 0.78 (Week 16). A trend in improvement in score was observed in all domains. Improvement in TIR had a positive, but weak, trend of association with improvement in overall treatment satisfaction (mean r = 0.14).
Conclusions: In people with T2D suboptimally controlled on ≥2 OADs ± GLP-1 RA, 16 weeks’ treatment with iGlarLixi resulted in a trend of improvement in treatment satisfaction.
Keywords: Patient Reported Outcomes; continuous glucose monitoring (CGM); fixed‐ratio combination; type 2 diabetes.
© 2025 The Author(s). Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.
